Alzheimer’s Trials Underscore the Gap Between Biomarkers and Clinical Benefit

Acumen plans to stop sabirnetug development after a Phase 2 trial failed to improve iADRS or key secondary outcomes despite amyloid-plaque reduction. A 40-person randomized Phase 1b study of IBC-Ab002 mainly assessed safety, with exploratory CSF and cognitive findings that do not establish efficacy; Phase 2 is planned for H1 2027. A small Cuban intranasal NeuroEPO plus trial reported cognitive improvement, but replication, durability, and safety follow-up remain necessary after a serious thrombosis and pulmonary embolism.